Stockwinners Market Radar for June 16, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:52 EDT Beam Global to acquire Amiga for EUR 10M - Beam Global announced the execution of a binding Letter of Intent to acquire European based Amiga DOO Kraljevo, a manufacturer of specialized structures and equipment, producing street lights, communications and energy infrastructure whose manufacturing, engineering and sales teams serve municipalities, states and commercial customers in 16 nations. The transaction is pending completion of Beam Global's due diligence, which will include customary closing conditions, and is expected to be finalized in Q3 or Q4 2023. Subject to completion of due diligence, including completion and review of an audit of Amiga's financial statements under U.S. GAAP, Beam Global is expected to acquire Amiga for EUR 10M of initial consideration splits as follows: (i) EUR 7M of cash of which EUR 4.5M will be paid at closing and an additional EUR 2.5M paid on Dec. 31, 2023 and (ii) EUR 3M in Beam Global's stock distributed in the same proportions and timing as the cash payments. The transaction also includes performance based earn-outs which would be distributed to Amiga shareholders based as follows: (i) 2023 earn-out paid in Beam Global's stock based on 2x the euro value of revenue above EUR 10M and (ii) 2024 earn-out paid in Beam Global's stock based on 2x the euro value of revenue above the greater of EUR 13.5M or 135% of 2023 revenue. As part of the consideration paid for Amiga, Beam Global will be receiving buildings and land independently valued at EUR 7M as well as plant and equipment independently valued at EUR 6M of replacement value.

17:34 EDT Ranger Oil shareholders approve transaction with Baytex Energy - Ranger Oil Corporation (ROCC) announced that the shareholders of Ranger voted in favor of all proposals associated with the previously announced merger with Baytex Energy (BTE). More than 99% of the votes cast were in favor of the transaction.

16:57 EDT Alphatec director Segal sells 71,329 common shares - In a regulatory filing, Alphatec Holdings director Paul Segal disclosed the sale of 71,329 common shares of the company on June 12 at a price of $15.15 per share.

16:40 EDT Cisco director McGeary sells 10,000 common shares - In a regulatory filing, Cisco director Roderick McGeary disclosed the sale of 10,000 common shares of the company on June 14 at a price of $50.9628 per share.

16:34 EDT Corporacion America Airport reports May passenger traffic up 29.6% y/y - Corporacion America Airport reported a 29.6% YoY increase in passenger traffic in May 2023, reaching 97.9% of May 2019 levels. Total passenger traffic grew 29.6% compared to the same month of 2022, supported by the ongoing recovery in travel demand after the Covid-19 pandemic and the gradual resumption of routes and frequencies across all countries of operations. Overall passenger traffic reached 97.9% of May 2019 levels, up from 95.4% posted in April, with international and domestic passenger traffic reaching 98.4% and 99.1% of May 2019 levels, respectively.

16:15 EDT Vince Holding CFO Levy resigns, Hand named interim CFO - Vince Holding Corp. announced Chief Financial Officer, Amy Levy, has resigned to pursue another opportunity. Levy will remain with the Company until June 30, 2023. "On behalf of the organization, I want to thank Amy for her leadership and contributions to Vince during her tenure. We wish her success in her future endeavors," said Jack Schwefel, Chief Executive Officer. The Company has appointed Michael Hand to serve as interim Chief Financial Officer, effective July 1, 2023. Mr. Hand is a seasoned corporate finance executive with over 40 years of financial, operations and general business experience in both public and private organizations. The majority of his career has been with growing consumer goods companies including retail, wholesale, e-commerce businesses. He has led financial and accounting teams at Marc Jacobs, Cole Haan, Coach, and Movado as well as Sotheby's and PepsiCo. Mr. Hand is a CPA and began his career at PricewaterhouseCoopers.

16:07 EDT Turtle Beach announces termination of rights agreement - Turtle Beach Corporation announced that its Board of Directors has unanimously approved the termination of the company's rights agreement, commonly referred to as a "poison pill", which was originally scheduled to expire on March 28, 2024. The rights agreement was amended to accelerate the expiration date to June 15, 2023, effectively terminating the agreement as of that date. "Turtle Beach is committed to enhancing its governance policies for the benefit of stockholders," said Terry Jimenez, Chairman of the Board. "The termination of the rights agreement advances that objective." Stockholders are not required, nor do they need to take any action because of the termination of the rights agreement.

16:00 EDT Guild Holdings Co trading resumes

15:27 EDT nCino up 16% after report of takeover interest from private equity firms - Shares of nCino are up $4.17, or 16%, to $29.63 after Reuters reported that the company is exploring its options, including a potential sale, after attracting takeover interest from private equity firms.

15:16 EDT nCino trading halted, volatility trading pause

14:43 EDT FDA panel recommends updated COVID-19 vaccines targeting XBB.1.5 subvariant - The FDA's Vaccines and Related Biological Products Advisory Committee met on June 15, 2023, to discuss and make recommendations for SARS-CoV-2 strain(s) for updated COVID-19 vaccines for use in the United States beginning in the fall of 2023. For the 2023-2024 formulation of the COVID-19 vaccines for use in the U.S. beginning in the fall of 2023, the committee unanimously voted that the vaccine composition be updated to a monovalent COVID-19 vaccine with an XBB-lineage of the Omicron variant. Following discussion of the evidence, the committee expressed a preference for XBB.1.5. During this meeting, the advisory committee was informed of the manufacturing timelines, they reviewed the available data on the circulation of SARS-CoV-2 virus variants, current vaccine effectiveness, human immunogenicity data of current vaccines against recently circulating virus variants, the antigenic characterization of circulating virus variants, animal immunogenicity data generated by new candidate vaccines expressing or containing updated spike components, and preliminary human immunogenicity data generated by one XBB.1.5 candidate vaccine. Based on the totality of the evidence, FDA has advised manufacturers who will be updating their COVID-19 vaccines, that they should develop vaccines with a monovalent XBB 1.5 composition. Publicly traded companies in the COVID-19 vaccine space include Moderna (MRNA), BioNTech (BNTX), Pfizer (PFE), Inovio (INO), AstraZeneca (AZN), Novavax (NVAX), and Johnson & Johnson (JNJ). Reference Link

14:09 EDT Upexi announces resignation of COO Anthony Bazan - In a regulatory filing, Upexi disclosed that on June 15 the company accepted the resignation of Anthony Bazan as Chief Operating Officer of the company. "There were no disagreements between Mr. Bazan and the company on any matter relating to the company's operations, policies or practices which resulted in his resignation," the filing stated.

13:56 EDT Navidea receives $7.5M cash from Cardinal Health in lieu of milestone payment - Navidea Biopharmaceuticals (NAVB) announced that on June 14 it entered into an amendment to the Asset Purchase Agreement, dated November 23, 2016, between the company and Cardinal Health 414, an affiliate of Cardinal Health (CAH). Under the terms of the amendment, Cardinal Health 414 paid the company $7.5M in cash on June 14 and the company waived its right to receive any contingent milestone payment that might otherwise become due and payable under the purchase agreement. "The cash payment from Cardinal Health 414 provides immediate capital for the company's Phase IIb and Phase III trials and related operations. Building on a history of partnership between the company and Cardinal Health, the amendment also aligns and supports growth goals related to Lymphoseek for both organizations. Prior to entering into the amendment with Cardinal Health 414, the company and Keystone Capital Partners agreed to terminate the letter of intent between them which outlined the material terms of the company's proposed sale of the Milestone Payment to Keystone for $8M. Supported by G2G Ventures as executive consultants, the company determined that the amendment with Cardinal Health 414 provided greater certainty of closing and accelerated funding without the inclusion of dilutive warrants. Keystone remains a trusted partner of the company and is expected to continue to assist the company in its future financing efforts," Navidea stated. "The amendment with Cardinal Health and equity line from Keystone Partners offers immediate capital and continuing positive support for Navidea's pioneering work. This is a great example of how a focused approach can drive the business forward, surface opportunities, strengthen relationships, and create shareholder return," said Dr. Jason Myers, Owner and Founder of G2G Ventures.

13:01 EDT Baker Hughes reports U.S. rig count down 8 to 687 rigs

12:34 EDT Mallinckrodt evaluating capital needs, extends $200M opioid payment - Mallinckrodt disclosed that its board is actively evaluating the company's capital needs in light of its obligations under its opioid settlement and its long-term debt, and is considering options, including transactions that have been proposed by holders of various series of the company's indebtedness and other stakeholders, as well as the viewpoints of various parties in interest. In connection with these ongoing discussions, on June 15, Mallinckrodt, certain subsidiaries of the company and the Opioid Master Disbursement Trust II entered into an amendment which extends to June 23, from June 16, the date on which a $200M payment is required to be made to the Trust. Mallinckrodt said it continues to analyze its situation and engage with various stakeholders, including representatives of the Trust. "There can be no assurance of the outcome of this process, including whether or not the Company may make a filing in the near term or later under the U.S. Bankruptcy Code or analogous foreign bankruptcy or insolvency laws," the company added.

12:21 EDT Abcam jumps 14% to $21.73 after disclosing multiple strategic inquiries

12:17 EDT Abcam received strategic inquiries 'from multiple parties' - In a letter to shareholders, Abcam said, "The Company has received strategic inquiries from multiple parties over recent weeks. The Board of Directors is aware of its fiduciary duties with respect to strategic inquiries and will work with its advisors to consider such inquiries as appropriate."

12:00 EDT Metals Acquisition falls -9.5% - Metals Acquisition is down -9.5%, or -$1.00 to $9.49.

12:00 EDT Wheels Up falls -11.9% - Wheels Up is down -11.9%, or -42c to $3.11.

12:00 EDT OneConnect rises 11.0% - OneConnect is up 11.0%, or 56c to $5.64.

11:56 EDT Teamsters approve strike authorization, UPS 'confident' will reach agreement - UPS stated in a post to its corporate newsroom: "The International Brotherhood of Teamsters announced it received approval from its UPS members who voted on its strike authorization. The results do not mean a strike is imminent and do not impact our current business operations in any way. Authorization votes and approvals are normal steps in labor union negotiations. We continue to make progress on key issues and remain confident that we will reach an agreement that provides wins for our employees, the Teamsters, our company and our customers." Reference Link

11:51 EDT LGL Group: Management transition remains in place - In April, the company formed a special purpose vehicle, Lynch Systems Acquisition Holding Company, LLC, to advance the Company's merchant business activities. This SPV forms part of the services business unit, Lynch Capital International LLC. LGL continues to pursue direct MNA lift outs and tuck in transactions to follow through on our growth initiatives. The company management transition remains in place as Michael Ferrantino finalizes the transitioning of continued operations, and will eventually resign his executive position following the satisfactory conclusion of the second quarter, while remaining on the LGL Board of Directors. As part of this transition, LGL is in the process of expanding its Board of Directors and is actively considering independent candidates having prior corporate transactional experience as well as persons who will expand the diversity of the board. Tim Foufas, a long time LGL board member, will join as Co-CEO along with Marc Gabelli, assuming the role vacated by Michael Ferrantino. This is subject to final approvals and ratification after Michael Ferrantino's transition.

11:36 EDT LiveOne expects total premium memberships to surpass 3M by year-end - LiveOne announced its total paid and ad-supported members have reached 3.1 Million, including over 2.2 million paid Members. LiveOne's CEO and Chairman, Robert Ellin, commented, "We are proud to continue our 9-year partnership with Tesla to deliver a streaming music service to Tesla owners consisting of a library of 30 million songs, 600 curated radio stations, and over 300 podcasts/vodcasts."

11:34 EDT ETFS Capital nominee Tonia Pankopf elected to WisdomTree board - ETFS Capital, the largest combined owner of common stock and Series A Non-Voting Convertible Preferred Stock of WisdomTree, with ownership of approximately 10.2% of the outstanding Common Stock, which together with its Series A Preferred Stock would represent approximately 18.3% of the Company's outstanding Common Stock on an as-converted basis, thanked fellow stockholders for their support of ETFS Capital's nominees at the 2023 annual meeting of stockholders. The firm said, "The election of ETFS Capital nominee Tonia Pankopf to the board of directors of the Company and the removal of the Company's long-tenured Board Chair Frank Salerno is a strong message from stockholders that the Board is in urgent need of meaningful change. Furthermore, Win Neuger, Chair of the Nominating and Governance Committee, received significant opposition with more than one-third of the shares voted at the annual meeting being against him based on preliminary results. ETFS Capital, on behalf of all stockholders, calls on the Board to heed the voices of stockholders who delivered a clear mandate and direction to the Board to reassess the causes of the Company's persistent underperformance, refocus WisdomTree around its core strengths, and to act as independent fiduciaries for stockholders by holding management to account. In addition, the Board has an obligation to demonstrate a commitment to stockholders to remove its long-tenured directors from key committee positions and to pursue true refreshment by reconstituting the leadership and key committees of the Board to include a plurality of independent views, experience, and expertise, particularly those of the more recently appointed directors. ETFS Capital intends to remain an engaged, constructive, and vigilant stockholder of WisdomTree."

11:09 EDT Navidea trading halted, news pending

10:31 EDT ISS recommends First Foundation shareholders vote for all 10 board nominees - First Foundation announced that Institutional Shareholder Services, a proxy advisory firm, has recommended that First Foundation stockholders vote for all of First Foundation's ten director nominees at the upcoming Annual Meeting of Stockholders scheduled for Tuesday, June 27, 2023. In its recommendation, ISS concludes that Driver has not made a compelling case for change: "From an operational performance standpoint, the company had delivered strong top-line and earnings growth over the last five years, mirrored by steady growth in assets, deposits, and loans, while maintaining a strong credit profile." Commenting on the recommendation, Scott F. Kavanaugh, President and CEO, said: "ISS recognizes that First Foundation has the right Board and the right strategy to continue enhancing value for stockholders. This unbiased third-party recommendation reaffirms the Board's conclusion that Driver did not make a compelling case for change and their nominee does not have the experience or expertise to be additive to the First Foundation Board."

10:05 EDT Vivendi agrees to sale of Editis to CMI group subsidiary - Vivendi announced that it has signed the agreement with the International Media Invest group, a CMI group subsidiary founded by Daniel Kretinsky, for the sale of 100% of the share capital of Editis. "Vivendi's signing of this agreement follows the opinion received from the Vivendi and Editis employee representative bodies. Following the authorization given by the European Commission to complete the transaction with the Lagardare group, IMI will need to be approved by the European Commission as a suitable purchaser. The transaction remains subject to IMI obtaining the required merger control clearances in the relevant jurisdictions. Completion is expected by early October 2023 at the latest," Vivendi stated.

10:00 EDT ATI Physical Therapy falls -6.3% - ATI Physical Therapy is down -6.3%, or -65c to $9.56.

10:00 EDT Huya rises 8.4% - Huya is up 8.4%, or 32c to $4.13.

10:00 EDT Virgin Galactic rises 34.7% - Virgin Galactic is up 34.7%, or $1.41 to $5.47.

09:47 EDT Cabot falls -7.5% - Cabot is down -7.5%, or -$5.58 to $69.04.

09:47 EDT Coherent rises 9.6% - Coherent is up 9.6%, or $4.95 to $56.22.

09:47 EDT Virgin Galactic rises 41.3% - Virgin Galactic is up 41.3%, or $1.68 to $5.74.

09:36 EDT Micron says half of China headquarter customer revenue at risk - Micron Technology disclosed that the impact of the May 21 Cybersecurity Administration of China on its business "continues to remain uncertain and fluid." Several Micron customers, including mobile phone makers, are being contacted by certain critical information infrastructure operators or representatives of the government in China concerning the future use of Micron products, the company said in a regulatory filing. As previously disclosed, Micron's revenue with companies headquartered in mainland China and Hong Kong, including direct sales as well as indirect sales through distributors, is approximately a quarter of Micron's worldwide revenue and remains the principal exposure. "We now believe that approximately half of that China HQ customer revenue, which equates to a low-double-digit percentage of Micron's worldwide revenue, is now at risk of being impacted," the company said. Micron added that it is working to mitigate this impact over time and expects increased quarter-to-quarter revenue variability. Micron's long-term goal is to retain its worldwide DRAM and NAND share, it said.

09:26 EDT Baidu launches fully driverless ride-hailing service in Shenzhen - Baidu has obtained licensing for commercial operation of its fully driverless ride-hailing service in Shenzen. Baidu robotaxis are now authorized to provide ride-hailing service with no safety operator present in the car, making Shenzen the fourth city in China where such service is available, following Wuhan, Chongqing and Bejing.

09:15 EDT Lexaria Bioscience provides update on DEM-A22-1, EPIL-A21-1 programs - As announced on November 10, 2022, study DEM-A22-1 was undertaken in thirty-two Long Evans rats using the established novel object recognition test, which is used to assess memory in rodents, in order to investigate whether DehydraTECH-CBD enables any pro-cognitive performance enhancements in this model, potentially of use in dementia treatment. The findings from this study were generally unremarkable and several unexpected study complications may have muted efficacy distinction ability. Most notably, the aged rats where cognitive impairment was expected to be most obvious did not, in fact, adequately exhibit this impaired tendency, making "improvements" difficult to measure. Also, animals in the high dose DehydraTECH-CBD cohort exhibited reduced locomotor activity, which may have indicated that treatment at this level produced sedative activity, also masking any prospective cognitive improvement. Together, these inconclusive results may point to required study design improvements necessary for a more concrete set of results. While this research did not produce any notable outcomes, Lexaria now recognizes that previous research by other investigators using CBD in this animal model has required dosing over a much longer duration, than Lexaria has thus far evaluated-. Lexaria will consider this if further testing is considered in future, potentially also including DehydraTECH-processed nicotine, as previously announced, as another agent known to enhance cognitive performance when effectively delivered. Epilepsy: EPIL-A21-1: As announced on November 29, 2022, Lexaria successfully completed two parts of its EPIL-A21-1 study program designed to evaluate the effectiveness of its DehydraTECH-CBD compared to one of the world's leading anti-seizure medications, Epidiolex, in reducing seizure activity using an established, vehicle-controlled, acute animal seizure model induced by electrical stimulation. The findings from this work appear to demonstrate that DehydraTECH-CBD had effectiveness at lower doses and with greater rapidity than Epidiolex. Since that time, Lexaria has also completed a final MES study under its EPIL-A21-1 program designed to establish an ED50 (i.e., the dose required to achieve seizure inhibition in 50% of the animals tested) for DehydraTECH-CBD in this animal model, where ED50 determination is a common performance metric in preclinical animal studies for developmental therapeutics. This ED50 study was designed with an objective to hopefully corroborate Lexaria's prior MES experimental findings. Lexaria is pleased to confirm that the outcome demonstrated that DehydraTECH-CBD was most effective at a dose of 75 mg/Kg, also as previously reported from the initial round of work in this animal model which compared favourably to Epidiolex that generally required a higher dose of 100 mg/Kg to achieve comparable findings.

09:08 EDT SciSparc, Clearmind to conduct study of obesity, metabolic syndrome treatment - SciSparc (SPRC) announced that as part of the Company's ongoing collaboration with Clearmind Medicine (CMND), a research agreement with the Hebrew University of Jerusalem was signed, to evaluate SciSparc's and Clearmind's proprietary combination treatment for obesity and metabolic syndrome. Professor Joseph Tam, D.M.D., Ph.D., the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem, will lead the study using the proprietary combination of SciSparc's PEA, and Clearmind's Methoxy-2-aminoindane, or MEAI. A previous pre-clinical study using MEAI, conducted at the Hebrew University of Jerusalem, under the leadership of Prof. Tam, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns. The study included three groups of rodents: lean rodents that were fed by a standard diet, obese rodents that were fed by a high-fat diet, and obese rodents that were fed by a high-fat diet along with MEAI treatment. The results of the prior study showed that obese animals, fed by high fat diet and treated with MEAI increased their energy expenditure, demonstrated better fat utilization and had weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation or well-being was observed. Additionally, the treatment yielded a normalization of insulin levels, improved glucose tolerance, and reduced fat and triglyceride accumulation in the liver. These results were significantly better than those obtained in the obese animals fed by high fat diet, untreated group. Furthermore, a significant reduction in sucrose preference was observed following the administration of MEAI for two days, supporting the notion that it can potentially dampen the hedonic value of rewarding stimuli. Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.

09:05 EDT PharmAla Biotech receives export permit to ship MDMA to University of Sydney - PharmAla Biotech announces the receipt of an export permit for the shipment of its allotment of GMP LaNeo MDMA to the University of Sydney. The shipment will mark the completion of the Company's $125,000 contract with the University of Sydney, which was previously announced on August 31, 2022.

09:03 EDT Algoma Steel reports fatal incident involving employee of contractor - Algoma Steel Group reports a fatal incident involving an employee of a contractor who was retained to perform specialized maintenance work. On the afternoon of June 15th, the worker lost consciousness while cleaning an out-of-service gas line. Algoma Steel Emergency Services personnel responded immediately with assistance from Sault Ste. Marie Fire and Paramedic Services. The worker was transported to Sault Area Hospital where they succumbed to their injuries. The Ministry of Labour has been notified and an investigation is underway.

09:01 EDT Osisko Gold announces closing of CSA stream transactions - Osisko Bermuda Limited (OR) closed the previously announced silver purchase agreement and copper purchase agreement with Metals Acquisition Limited (MTAL) concurrently with the closing of the acquisition by MAC of the producing CSA mine in New South Wales, Australia from a subsidiary of Glencore (GLNCY). The closing date of the Metals Stream and Acquisition Transaction was June 15, 2023. TRANSACTION HIGHLIGHTS: Immediately Enhances Osisko's Cash Flow: Starting with an effective date of February 1, 2023, OBL will purchase refined silver equal to 100% of payable silver for the life of the Mine. Between 2023-2025, MAC estimates annual payable silver production from the Mine to average ~428koz.; Beginning on the first anniversary of the Closing Date, OBL will purchase refined copper equal to between 3.0% and 4.875% of payable copper until 33,000 metric tonnes of refined copper have been delivered, and 2.25% thereafter for the remaining life of the Mine. Between 2023-2025, MAC estimates annual payable copper production from the Mine to average ~46,000 metric tonnes. Exposure to Premium Copper Asset in a Tier 1 Mining Jurisdiction: One of the highest-grade copper mines in Australia with a multi-decade operating history of consistent production. Track-record of reserve and resource replacement, with greater than 100% of mined reserves having been replaced since 2011. Recent investments of approximately US$130 million support potential mine life extensions beyond 15 years. Near-Term Opportunities to Extend Mine Life and Enhance Value: Significant exploration potential from both near-mine and regional targets along a highly prospective geological trend. Several areas identified to improve efficiencies, optimize operations and rationalize costs. Significant resource and mine life upside by potentially lowering the cut-off grade. Experienced Management Team with Track-Record of Creating Value for Stakeholders: Proven Australian mining professionals with extensive mining experience and a track-record of value creation for stakeholders. Partnership opportunities on future strategic activity, as well as a right of first refusal in favour of OBL on royalties or streams on any asset owned or acquired by MAC for a minimum of seven years following the Closing Date. METALS STREAMS DETAILS: Silver Stream: OBL has made an upfront cash deposit to MAC of US$75 million. OBL will purchase an amount of refined silver equal to 100% of the payable silver produced from CSA for the life of the Mine and will make ongoing payments for refined silver delivered equal to 4% of the spot silver price at the time of delivery. Between 2023-2025, MAC estimates payable silver production from the Mine to average ~428koz per annum. Copper Stream: OBL has made an upfront cash deposit to MAC of US$75 million. OBL will purchase refined copper equal to the following amounts of payable copper produced from CSA: from the Closing Date until the 1st anniversary of the Closing Date, nil; from the 1st anniversary of the Closing Date to the 5th anniversary of the Closing Date, 3.00%; from the 5th anniversary of the Closing Date until 33,000 metric tonnes of refined copper have been delivered to OBL, 4.875%; and thereafter, 2.25% for the remaining life of the Mine. Between 2023-2025, MAC estimates payable copper production from the Mine to average ~46,000 metric tonnes per annum. OBL will make ongoing payments for refined copper delivered equal to 4% of the spot copper price at the time of delivery. On the 5th anniversary of the Closing Date, MAC may elect to exercise one of two buy-down options with respect to the Copper Stream: reduce the Second Threshold Stream from 4.875% to 3.25% and the Tail Stream from 2.25% to 1.50% and reduce the threshold volume between the Second Threshold Stream and the Tail Stream from 33,000 metric tonnes to 23,900 metric tonnes by paying a one-time cash payment to OBL of US$40 million; or reduce the Second Threshold Stream from 4.875% to 4.0625% and the Tail Stream from 2.25% to 1.875% and reduce the threshold volume between the Second Threshold Stream and the Tail Stream from 33,000 metric tonnes to 28,450 metric tonnes by paying a one-time cash payment to OBL of US$20 million.

08:47 EDT CCL Industries to acquire Pouch Partners, Italy for $44M - CCL Industries has signed a binding agreement today to acquire Pouch Partners s.r.l., Italy, from Pouch Partners AG, Switzerland, a company owned by Swiss headquartered Capri-Sun Group. Pouch Partners supplies highly-specialized, gravure printed & laminated, flexible film materials for pouch forming, including recyclable solutions, with 2022 sales of $104 million and adjusted EBITDA of $6.8 million. The debt free, all cash purchase consideration is $44 million, subject to customary adjustments at closing, scheduled for the 2023 third quarter. The new business will then trade as CCL Specialty Pouches and become an integral part of CCL Label's Food & Beverage unit in Europe.

08:32 EDT Actelis Networks launches line of layer 2, layer 3 fiber optic switching devices - Actelis Networks announced the launch of a new line of advanced, software managed, temperature and cyber-hardened, layer 2 and layer 3 fiber optic switching devices. This release will enable Actelis to deliver a much broader selection of solutions for large and small networks, at higher speeds, in support of hybrid-fiber-copper networks that contain a larger part of fiber. The launch includes the following product series: GL5010; GL5020; GL5030; GL5060; GL5070; GL5080; GL6010; GL6030; GL6040X. This major release of nine new GigaLine product families and more than 40 product models, is comprised of 10Gbps layer 2 and layer 3 switches and aggregation devices, offering a wide range of features and benefits, and is a follow up on the previous releases of Actelis' GigaLine product offerings for copper, coax and hybrid-fiber-copper networking products.

08:31 EDT Microbot Medical announces peer reviewed abstracts accepted b CIRSE - Microbot Medical is encouraged by the continued participation and level of enthusiasm being demonstrated by the Key Opinion Leaders globally who are using the LIBERTY Robotic Surgical System during the Company's pre-clinical animal studies. Further displaying their positive experiences and satisfaction, the Company has been informed that two peer-reviewed abstracts have been accepted to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe, CIRSE. In addition, one of the abstracts was accepted as an oral presentation. "Our goal is to increase awareness amongst leading KOLs to LIBERTY while we establish the necessary data for our regulatory process, primarily for the FDA. We believe that the current and future peer-reviewed data will accelerate adoption of LIBERTY once commercialized," said Dr. Eyal Morag, Chief Medical Officer of Microbot Medical. "The physician's desire to take part in our studies and submit a peer-review abstract, as well as accepted by one of the biggest interventional radiology societies, is a testimony of our disruptive solution."

08:20 EDT Tyler Technologies targets $3.6B-$3.8B in revenue by 2030 - Sees 10%-12% organic recurring revenue growth, recurring revenue at over 90%, free cash flow margins in the "high 20s%", and free cash flow reaching about $1B. Comments taken from investor presentation slides. Reference Link

08:05 EDT Perspective announces information on Celsium-131 to be presented at ABS - Perspective Therapeutics announced that the growing body of information regarding Cesium-131 brachytherapy in the treatment of prostate cancer will be highlighted in two presentations at the 2023 American Brachytherapy Society, ABS, Annual Meeting to be held in Vancouver, British Columbia, Canada from June 21-24, 2023. "We are delighted that long-term clinical data on the benefits of Cesium-131 brachytherapy for prostate cancer will be presented at this year's ABS Annual Meeting," said Thijs Spoor, Perspective Therapeutics' Chief Executive Officer. He added, "We're also excited to note that the American Brachytherapy Society is including a session entitled, 'Implementation of Radiopharmaceuticals in the Radiation Oncology Clinic'. With our focus on alpha-particle radiopharmaceuticals and Cesium-131 brachytherapy we're closely aligned with ABS's interests." Presentation #1 Title: "Prostate Brachytherapy with Cs-131: Long Term Results Compared to Published SBRT Data." The authors of presentation 1 noted that Cesium-131 LDR brachytherapy provided excellent disease-free survival rates at 5 and 10 years, comparable with recently published Stereotactic Body Radiation Therapy outcomes. It was noted that 47% of the brachytherapy patients had intermediate risk disease as compared to all low risk patients in the SBRT data. Presentation #2: Title: "All Isotopes Are Not Created Equal but Does One Stand Out?" Ryan P. Smith, MD will share his long term experience with Cesium-131.

08:03 EDT Enviri to begin trading under new NYSE ticker on June 20 - Enviri Corporation, formerly Harsco Corporation (HSC), announced that its New York Stock Exchange Ticker Symbol will begin trading under (NVRI) at market open on Tuesday, June 20, 2023. The NYSE Ticker change comes two weeks after the Company announced it was changing its name to Enviri Corporation from Harsco Corporation. While the Company has changed its legal name to Enviri, its segments - Harsco Environmental, Clean Earth and Harsco Rail - will continue to operate under their existing names.

08:02 EDT Bitdeer board approves $1M share repurchase program - Bitdeer Technologies board of directors has approved a share repurchase program under which the Company may repurchase up to $1,000,000 worth of its Class A ordinary shares, effective through September 15, 2023.

07:59 EDT iRobot up 23% at $51.56 after its acquisition by Amazon.com was cleared by CMA

07:30 EDT Titan Medical announces lifting of management cease trade order - Titan Medical reports that the management cease trade order granted on April 3, 2023 by the Ontario Securities Commission under National Policy 12-203 - Management Cease Trade Orders lapsed on June 13, 2023 following the filing, on May 31, 2023, of the Company's annual financial statements and accompanying management's discussion and analysis for the fiscal year ended December 31, 2022 and the filing, on June 9, 2023, of the Company's first quarter financial statements and accompanying management's discussion and analysis for the period ended March 31, 2023.

07:08 EDT Janus International Group appoints Pete Frayser chief commercial officer - Janus International Group announced the appointment of Pete Frayser to the newly created position of chief commercial officer, effective June 12. He will be based in Atlanta, Georgia and report directly to Janus's CEO, Ramey Jackson.

07:06 EDT Surface Oncology implements 50% workforce reduction - In conjunction with the transaction announcement, Surface is implementing a workforce reduction of approximately 50% of its employees.

07:06 EDT Origin Materials CFO Nate Whaley to depart - Origin Materials announced that CFO Nate Whaley will be departing the company and the company has initiated a formal search process for the selection of its new CFO. Whaley will remain at the company until September 1 and will hold an advisory role with Origin through the end of the year to assist the company with the search for and onboarding of his successor, ensuring sufficient time for a transition.

07:05 EDT Jeffs' Brands announces launch of new wholesale channel - Jeffs' Brands (JFBR) announced that it has launched new wholesale channel targeting potential organizations and institutional clients, following an increased demand for its pest control products. The needs of clients from the institutional market, as opposed to the consumer market, are typically characterized by the need for more sophisticated solutions for pest control and orders in large quantities. Such clients usually do not place online orders on consumer platforms such as the Amazon Marketplace (AMZN). To address the needs of such institutional clients, the Company will launch a new industrial product line. To fulfill potential orders, the Company has set up an online direct sales platform and a suitable supply chain. "The Fort brand's products were our latest acquisition, and we are extremely pleased with their performance since the beginning of the year. As we are constantly seeking ways to expand our brands' reach, we identified the growing demand from the institutional market for robust solutions for pest control," said Viki Hakmon, Chief Executive Officer of the Company. "Following profound market research, we laid the complete infrastructure to meet the requirement of the market as well as developing new dedicated products and marketing channels. Years of extensive experience in online marketing enabled us to target this fast- growing market and introduce our products. We are optimistic about the potential of the institutional market and our ability to penetrate it."

07:03 EDT Autolus Therapeutics presents results from AUTO04 in Phase 1/2 LibrA T1 study - Autolus Therapeutics announces clinical data of AUTO4, a TRBC1-targeting CAR T cell therapy in relapsed/refractory TRBC1-Positive Peripheral T-Cell Lymphoma at the International Conference on Malignant Lymphoma being held June 13 to 17, 2023 in Lugano, Switzerland. The LibrA T1 trial is a single arm, open label, multi-center, Phase 1/2 study evaluating the safety and efficacy of AUTO4, a single dose intravenous CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1-positive selected PTCL. Overall, the treatment was well tolerated with no dose limiting toxicities. In Process A, at the highest dose tested, 4 out of 4 patients achieved a response with 2 out of 4 remaining in ongoing complete metabolic response at 15 and 18-months post-dose, respectively. Presence of CAR T cells in the lymph nodes of patients suggest fast homing of CAR T cells to the tumor site, despite absence in the blood. Efficacy data from Process B was not provided given median follow up is less than3 months. "AUTO4, with its unique targeting mechanism, represents an opportunity for advanced programmed T cell therapies that will make a difference in patients who traditionally suffer from severe immunosuppression as a result of current therapeutic options," said Dr. Edgar Braendle, Chief Development Officer of Autolus. "This is a trial with a small number of patients, but with all 4 patients at the highest dose in the study achieving a response and 2 out of the 4 remaining in a complete metabolic response beyond 12 months, AUTO4 shows potential to provide a novel therapy option for PTCL patients."

06:47 EDT Merck: Phase 3 KEYNOTE-811 trial met one of two endpoints - Merck announced that the Phase 3 KEYNOTE-811 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with trastuzumab and chemotherapy met one of its dual primary endpoints of progression-free survival for the first-line treatment of human epidermal growth factor receptor 2-positive advanced gastric or gastroesophageal junction adenocarcinoma. At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with trastuzumab and chemotherapy demonstrated a statistically significant improvement in PFS compared to placebo in combination with trastuzumab and chemotherapy in the intention-to-treat study population. Based on a pre-specified subgroup analysis by PD-L1 expression, the improvement in PFS observed in the ITT population was limited to patients whose tumors were PD-L1 positive. In the study, more than 80% of patients had tumors that were PD-L1 positive. Merck has discussed these findings with the U.S. FDA and is working with the FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma to those patients whose tumors are PD-L1 positive. In addition, these results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.

06:35 EDT GSK announces extension of FDA review period for momelotinib - GSK plc announced that the U.S. Food and Drug Administration has extended the review period of the new drug application, or NDA, for momelotinib by three months to provide time to review recently submitted data. The extended action date is September 16, 2023. "GSK is confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review. Momelotinib is not currently approved in any market," the company stated.

06:05 EDT Townsquare Media repurchases 1.5M shares for $9.70 per share - Townsquare Media announced that it has repurchased, and subsequently retired, 1.5M shares of Class C common stock held by MSG National Properties for $9.70 per share. The purchase price reflects a 8.5% discount from the closing price of the Class A common stock on June 15. Following this transaction, MSG will own 1,708,139 shares of common stock in the company. The purchase price of $14.6M was funded with cash on hand.

06:03 EDT VCI Global, Fusionex enter talks to establish partnership - VCI Global announced that it has entered into discussions with the Fusionex Group to establish a mutually beneficial exclusive collaboration between both parties. This partnership envisages VCI Global providing AI and big data consulting services to its clients. With a primary focus on Southeast Asia, while keeping opportunities open worldwide, VCI Global has selected Fusionex as its technology partner. The global AI market, estimated to be valued between $110B and $120B in 2022, presents immense potential for growth. Furthermore, industry projections indicate that the Asia Pacific market is poised to grow at a compound average rate of 35% to 40% from 2022 to 2030. Leveraging Fusionex's Analytics GIANT solution, VCI Global aims to deliver value and strategic guidance to its clientele. With its expertise in analytics, Big Data, machine learning, and AI, the multi-award-winning data technology market leader, Fusionex, empowers its clients in managing invaluable insights from the vast amounts of data available.

05:52 EDT Squarespace confirms agreement to acquire Google Domains assets - Squarespace (SQSP) announced Thursday it has entered into a definitive asset purchase agreement with Google (GOOGL), whereby Squarespace will acquire the assets associated with the Google Domains business, which will be winding down following a transition period. This purchase includes approximately 10 million domains hosted on Google Domains spread across millions of customers. "We are exceptionally proud to be chosen to serve the customers of the Google Domains business," said Anthony Casalena, Founder & CEO of Squarespace. Under the terms of the agreement, Squarespace will honor all existing Google Domains customers' renewal prices for at least 12 months following the closing of the transaction, as well as provide additional incentives to encourage Google Domains customers to build a website with Squarespace and adopt other Squarespace offerings. Further, Squarespace will be leveraging Google's infrastructure powering the Google Domains product during the migration period in order to ensure the seamless transfer of domains. The transaction is expected to close in the third quarter of 2023, and is subject to certain regulatory approvals and customary closing conditions. While the majority of the benefits of this deal will be realized in 2024 and beyond, Squarespace believes this deal will be meaningfully accretive to its business from both a revenue and free cash flow perspective over time.

05:37 EDT LyondellBasell, AFA Nord to form 50:50 recycling joint venture - LyondellBasell and AFA Nord, a recycler of agricultural film, have agreed to create a 50:50 joint venture that intends to recycle post commercial flexible secondary packaging waste. The joint venture company, LMF Nord, plans to build a mechanical recycling plant in Northern Germany to turn Linear Low Density Polyethylene and Low Density Polyethylene waste into quality recycled plastic materials for use in flexible packaging. Start of production is expected for early 2025.

05:32 EDT Cadeler, Eneti to combine through stock-for-stock exchange offer - Cadeler and Eneti, two offshore wind turbine and foundation installation companies, announced that they have entered into a business combination agreement to combine through a stock-for-stock exchange offer to be made to all stockholders of Eneti based on an exchange ratio of 3.409 Cadeler shares for each Eneti share. Following the completion of the exchange offer, Cadeler and Eneti shareholders will own approximately 60% and 40% of the combined company, respectively, on the basis of the share counts for each of Cadeler and Eneti and assuming all outstanding Eneti shares are exchanged for Cadeler shares in the exchange offer. The combined group will be named Cadeler, and be headquartered in Copenhagen, Denmark, with its shares to be listed on the New York Stock Exchange in addition to its current listing on the Oslo Stock Exchange. The business combination agreement has been unanimously approved by the board of each of Cadeler and Eneti. Eneti's largest shareholder, together with certain of its affiliates collectively holding approximately 29% of all of the issued and outstanding shares of common stock in Eneti, and Eneti's directors and executive officers, collectively holding approximately 7% of the issued and outstanding shares of common stock in Eneti, have entered into tender and support agreements in favor of the combination. In addition, Cadeler's two largest shareholders, together in aggregate currently owning approximately 45% of the total current share capital and voting rights of Cadeler, have entered into voting undertakings to vote in favor of the shareholder approval to be obtained by Cadeler. The combination is anticipated to deliver run rate annual synergies of EUR 106M, excluding transaction and change of control cost, comprising corporate and financing synergies of EUR 18M, operational synergies of EUR 37M and EUR 51M through improved utilization of the combined fleets. While the cost synergies are expected to be frontloaded, the targeted utilization synergies are expected to be generated as the newbuilds enter into operation. To facilitate the completion of the Combination, Cadeler will in connection with amendments to its existing financing arrangements increase its total available debt financing facilities including for general corporate and working capital purposes and in addition hereto obtain a credit approved financing commitment to refinance the long-term debt obligation for the combined company's fleet on the water at attractive terms, subject to completion of the combination and definitive documentation. The transaction is structured as a voluntary conditional registered exchange offer to the stockholders of Eneti, to be initiated by Cadeler with an exchange ratio of 3.409 Cadeler shares for each Eneti share. Based on Cadeler's share price of NOK 47.68 per share and an exchange rate of NOK/USD 0.10, the proposed combination would value each outstanding Eneti share at approximately $15.44 and the fully diluted share capital of Eneti at approximately $597M. The Cadeler shares are currently expected to be delivered to Eneti shareholders in the form of American Depositary Shares representing Cadeler shares. Upon completion of the combination, Cadeler and Eneti shareholders will own approximately 60% and 40% of the combined company, respectively, on the basis of the 197,600,000 shares outstanding for Cadeler and 38,647,119 shares outstanding for Eneti and assuming all outstanding Eneti shares are exchanged for Cadeler shares in the combination. In addition, if, following completion of the exchange offer, Cadeler has acquired or controls at least 85.01% of the issued and outstanding Eneti shares and voting rights and no other legal impediment to a squeeze-out merger exists, Cadeler intends, indirectly through a wholly-owned subsidiary, to initiate a squeeze-out merger under Marshall Islands law such that, following the merger, Eneti will be a wholly owned subsidiary of Cadeler. The precise consideration minority Eneti shareholders may receive in such merger may be different in form and/or value from the consideration that they would have received had they tendered their Eneti shares in the exchange offer. Cadeler moreover intends to eliminate companies in the Eneti group structure incorporated in any jurisdiction on the EU's list of non-cooperative jurisdictions for tax purposes, as adopted by the Counsel of EU in due course following completion of the Combination and to the extent feasible from a legal perspective. The Combination is subject to customary closing conditions, including amongst others shareholder approval of an authorization to the board of Cadeler to issue new Cadeler shares in the exchange offer to be adopted by a 2/3 majority of share capital and voting rights represented at an extraordinary shareholders meeting of Cadeler and acceptance of the proposed tender offer by at least 85.01% of all outstanding Eneti shares, the absence of a material adverse change, the receipt of merger clearance as well as any applicable foreign direct investment approvals and approval for the listing of the combined company's shares on each of the NYSE and OSE. The offer period for the exchange offer will not commence until the offer and listing documentation has been duly reviewed and, if applicable, approved by all relevant regulatory bodies and will not conclude prior to the registration with the U.S. Securities and Exchange Commission of the Cadeler shares to be offered for exchange. The exchange offer is expected to commence in the third or fourth quarter of 2023. The combination is currently expected to close in Q4 2023 subject to regulatory approvals and applicable conditions being met.

05:14 EDT Intel plans to invest $4.6B in semiconductor assembly, test facility in Poland - Intel announced that it has selected an area near Wrocaw, Poland, as the site of a semiconductor assembly and test facility. This facility will help meet critical demand for assembly and test capacity that Intel anticipates by 2027. Intel expects to invest up to $4.6B in the facility, which will have the capacity to expand. When completed, the facility will support approximately 2,000 Intel employees. The construction of the facility is also expected to create several thousand more jobs, in addition to eventual hiring by suppliers. Design and planning for the facility will begin immediately, with construction to commence pending European Commission approval.